Development of inhaled moxifloxacin-metformin formulation as an alternative for pulmonary tuberculosis treatment.
Simon A, Velloso-Junior SO, Mesquita RD, Fontao APGA, Costa TEMM, Honorio TS, Guimaraes TF, Sousa EGR, Viçosa AL, Sampaio ALF, do Carmo FA, Healy AM, Cabral LM, Castro RR.
Simon A, et al. Among authors: cabral lm.
Int J Pharm. 2024 Dec 5;666:124740. doi: 10.1016/j.ijpharm.2024.124740. Epub 2024 Sep 26.
Int J Pharm. 2024.
PMID: 39341387